Cited by 522Cancer Immunotherapy and BiomarkersMedical Imaging Techniques and ApplicationsCutaneous Melanoma Detection and Management

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

Open access

Nishino, Mizuki, Giobbie-Hurder, Anita, Gargano, Maria, Suda, Margaret, Ramaiya, Nikhil H., Hodi, F. Stephen·2013·Clinical Cancer Research

DOI 10.1158/1078-0432.ccr-13-0895PMC PMC3740724

Open this paper in CoChat — free account

Abstract

PURPOSE: Immune-related response criteria (irRC) was developed to adequately assess tumor response to immunotherapy. The irRC are based on bidimensional measurements, as opposed to unidimensional measurements defined by Response Evaluation Criteria in Solid Tumors, which has been widely used in solid tumors. We aimed to compare response assessment by bidimensional versus unidimensional irRC in patients with advanced melanoma treated with ipilimumab. EXPERIMENTAL DESIGN: Fifty-seven patients with advanced melanoma treated with ipilimumab in a phase II, expanded access trial were studied. Bidimensional tumor measurement records prospectively conducted during the trial were reviewed to generate a second set of measurements using unidimensional, longest diameter measurements. The percent changes of measurements at follow-up, best overall response, and time-to-progression (TTP) were compared between bidimensional and unidimensional irRC. Interobserver variability for bidimensional and unidimensional measurements was assessed in 25 randomly selected patients. RESULTS: The percent changes at follow-up scans were highly concordant between the 2 criteria (Spearman r: 0.953-0.965, first to fourth follow-up). The best immune-related response was highly concordant between the 2 criteria (κw = 0.881). TTP was similar between the bidimensional and unidimensional assessments (progression-free at 6 months: 70% vs. 81%, respectively). The unidimensional measurements were more reproducible than bidimensional measurements, with the 95% limits of agreement of (-16.1%, 5.8%) versus (-31.3%, 19.7%), respectively. CONCLUSION: irRC using the unidimensional measurements provided highly concordant response assessment compared with the bidimensional irRC, with less measurement variability. The use of unidimensional irRC is proposed to assess response to immunotherapy in solid tumors, given its simplicity, higher reproducibility, and high concordance with the bidimensional irRC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-13-0895

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citation
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
A concordance correlation coefficient to evaluate reproducibility.
Lin, L. I.-K. (1989) · Biometrics · doi:10.2307/2532051 · Cited by 8,785
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195

Show all 21 references

Sorted by citations

Items 101–200 of 520

Targeted Therapy and Immunotherapy in the Treatment of Non–Small Cell Lung Cancer
Shroff, G. S., de Groot, P. M., Papadimitrakopoulou, V. A., Truong, M. T., & Carter, B. W. (2018) · Radiologic Clinics of North America · doi:10.1016/j.rcl.2018.01.012 · Cited by 78
Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies
Siu, L. L., Ivy, S. P., Dixon, E. L., Gravell, A. E., Reeves, S. A., & Rosner, G. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3079 · Cited by 75
Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
Lu, L., Hsu, C., Shao, Y., Chao, Y., Yen, C., Shih, I., Hung, Y., Chang, C., Shen, Y., Guo, J., et al. (2019) · Liver Cancer · doi:10.1159/000501275 · Cited by 79
Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
Autio, K. A., Klebanoff, C. A., Schaer, D., Kauh, J. S. W., Slovin, S. F., Adamow, M. J., Blinder, V. S., Brahmachary, M., Carlsen, M., Comen, E. A., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0855 · Cited by 72
Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study
Jespersen, H., Bagge, R. O., Ullenhag, G. J., Carneiro, A., Helgadóttir, H., Ljuslinder, I., Levin, M., All‐Eriksson, C., Andersson, B. A., Stierner, U. K., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5623-3 · Cited by 70
Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications
Decazes, P., & Bohn, P. (2020) · Cancers · doi:10.3390/cancers12020371 · Cited by 74
Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
Luke, J. J., Barlési, F., Chung, K. Y., Tolcher, A. W., Kelly, K. L., Hollebecque, A., Tourneau, C. L., Subbiah, V., Tsai, F. Y.-C., Kao, S., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002015 · Cited by 68
Do immune checkpoint inhibitors need new studies methodology?
Ferrara, R., Pilotto, S., Caccese, M., Grizzi, G., Sperduti, I., Giannarelli, D., Milella, M., Besse, B., Tortora, G., & Bria, E. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.131 · Cited by 69
MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy
Jiang, X., Dudzinski, S. O., Beckermann, K. E., Young, K. L., McKinley, E. T., McIntyre, J. O., Rathmell, J. C., Xu, J., & Gore, J. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000328 · Cited by 65
Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study
Lyu, N., Kong, Y., Li, X., Mu, L., Deng, H., Chen, H., He, M. X., Lai, J., Li, J., Tang, H., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.580241 · Cited by 67
A First-in-Human Phase I Study of INVAC-1, an Optimized Human Telomerase DNA Vaccine in Patients with Advanced Solid Tumors
Teixeira, L., Médioni, J., Garibal, J., Adotévi, O., Doucet, L. S., Dragon‐Durey, M., Ghrieb, Z., Kiladjian, J., Brizard, M., Laheurte, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1614 · Cited by 65
Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
Nishino, M., Giobbie‐Hurder, A., Ramaiya, N. H., & Hodi, F. S. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0040-2 · Cited by 61
Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer
Ragoonanan, D. S., Khazal, S. J., Abdel‐Azim, H., McCall, D. C., Cuglievan, B., Tambaro, F. P., Ahmad, A. H., Rowan, C. M., Gutiérrez, C., Schadler, K., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00474-4 · Cited by 62
A randomized phase 2 trial of nivolumab, gemcitabine, and cisplatin or nivolumab and ipilimumab in previously untreated advanced biliary cancer: BilT ‐01
Sahai, V., Griffith, K. A., Beg, M. S., Shaib, W. L., Mahalingam, D., Zhen, D. B., Deming, D. A., & Zalupski, M. M. (2022) · Cancer · doi:10.1002/cncr.34394 · Cited by 61
Advanced Renal Cell Carcinoma: Role of the Radiologist in the Era of Precision Medicine
Shinagare, A. B., Krajewski, K. M., Braschi‐Amirfarzan, M., & Ramaiya, N. H. (2017) · Radiology · doi:10.1148/radiol.2017160343 · Cited by 61
Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET–CT
Dimitrakopoulou‐Strauss, A. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2229-6 · Cited by 61
CCR 20th Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology
Hoos, A., Wolchok, J. D., Humphrey, R. W., & Hodi, F. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3128 · Cited by 61
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy.
Solinas, C., Porcu, M., Hlavatá, Z., Silva, P. D., Puzzoni, M., Willard-Gallo, K., Scartozzi, M., & Saba, L. (2017) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2017.09.017 · Cited by 57
Tumor response assessment on imaging following immunotherapy
Berz, A. M., Dromain, C., Violi, N. V., Boughdad, S., & Durán, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.982983 · Cited by 62
Immunotherapy for pancreatic cancer
Yoon, J. H., Jung, Y.-J., & Moon, S. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i13.2969 · Cited by 58
Radiologic Heterogeneity in Responses to Anti–PD-1/PD-L1 Therapy in Metastatic Renal Cell Carcinoma
de Velasco, G., Krajewski, K. M., Albiges, L. K., Awad, M. M., Joaquim Bellmunt, B., Hodi, F. S., & Choueiri, T. K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0197 · Cited by 58
Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer
Zhang, C., Chong, X., Jiang, F., Gao, J., Chen, Y., Jia, K., Fan, M., Liu, X., An, J., Li, J., et al. (2022) · Journal of Extracellular Vesicles · doi:10.1002/jev2.12209 · Cited by 56
Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment
Nishino, M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0134-0 · Cited by 57
Immunotherapy in Non–Small Cell Lung Cancer Treatment
Carter, B. W., Halpenny, D. F., Ginsberg, M. S., Papadimitrakopoulou, V. A., & de Groot, P. M. (2017) · Journal of Thoracic Imaging · doi:10.1097/rti.0000000000000291 · Cited by 57
Comparing available criteria for measuring brain metastasis response to immunotherapy
Qian, J. M., Mahajan, A. K., Yu, J. B., Tsiouris, A. J., Goldberg, S. B., Kluger, H. M., & Chiang, V. (2017) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2398-8 · Cited by 54
ANO1‐Mediated Inhibition of Cancer Ferroptosis Confers Immunotherapeutic Resistance through Recruiting Cancer‐Associated Fibroblasts
Jiang, F., Jia, K., Chen, Y., Ji, C., Chong, X., Li, Z., Zhao, F., Bai, Y., Ge, S., Gao, J., et al. (2023) · Advanced Science · doi:10.1002/advs.202300881 · Cited by 52
Comparison Between 18F-FDG PET–Based and CT-Based Criteria in Non–Small Cell Lung Cancer Patients Treated with Nivolumab
Rossi, G., Bauckneht, M., Genova, C., Rijavec, E., Biello, F., Mennella, S., Bello, M. G. D., Cittadini, G., Bruzzi, P., Piva, R., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.233056 · Cited by 52
Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer
Xu, Y., Li, H., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642883 · Cited by 54
PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions
Eze, C., Schmidt-Hegemann, N.-S., Sawicki, L. M., Kirchner, J., Roengvoraphoj, O., Käsmann, L., Mittlmeier, L. M., Kunz, W. G., Tufman, A., Dinkel, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05211-8 · Cited by 54
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
Chawla, S. P., Tine, B. A. V., Pollack, S. M., Ganjoo, K. N., ELIAS, A. D., Riedel, R. F., Attia, S., Choy, E., Okuno, S. H., Agulnik, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03452 · Cited by 52
Deciphering radiological stable disease to immune checkpoint inhibitors
Luo, J., Wu, S., Rizvi, H. A., Zhang, Q., Egger, J. V., Osorio, J. C., Schoenfeld, A. J., Plodkowski, A. J., Ginsberg, M. S., Callahan, M. K., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.04.450 · Cited by 52
Radiation Therapy Intensification for Solid Tumors: A Systematic Review of Randomized Trials
Yamoah, K., Showalter, T. N., & Ohri, N. (2015) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2015.07.2284 · Cited by 51
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer
Ferrara, R., Imbimbo, M., Malouf, R. S., Paget‐Bailly, S., Calais, F., Marchal, C., & Westeel, V. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013257.pub2 · Cited by 51
PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
Wang, J., Li, M., Zhang, Y., Teng, F., Han, A., Kong, L., & Zhu, H. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s94993 · Cited by 54
A Prospective, Phase 1 Trial of Nivolumab, Ipilimumab, and Radiotherapy in Patients with Advanced Melanoma
Postow, M. A., Knox, S. J., Goldman, D. A., Elhanati, Y., Mavinkurve, V., Wong, P., Halpenny, D. F., Reddy, S. A., Vado, K., McCabe, D., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3936 · Cited by 49
Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response
Wu, M., Zhang, Y., Zhang, Y., Liu, Y., Wu, M., & Ye, Z. (2019) · Radiology Imaging Cancer · doi:10.1148/rycan.2019190031 · Cited by 47
Non-invasive CT imaging biomarker to predict immunotherapy response in gastric cancer: a multicenter study
Huang, W., Xiong, W., Tang, L., Chen, C., Yuan, Q., Zhang, C., Zhou, K., Sun, Z., Zhang, T., Han, Z., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007807 · Cited by 47
Checkpoint Blockade for the Treatment of Advanced Melanoma
Callahan, M. K., Flaherty, C., & Postow, M. A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-22539-5_9 · Cited by 49
Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature
Zhou, L., Zhang, M., Li, R., Xue, J., & Lü, Y. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03360-1 · Cited by 47
Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells
Kirkin, A. F., Dzhandzhugazyan, K. N., Guldberg, P., Fang, J., Andersen, R. S., Dahl, C., Mortensen, J., Lundby, T., Wagner, A., Law, I. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03217-9 · Cited by 46
A Radiologist's Guide to Response Evaluation Criteria in Solid Tumors
Lalchandani, U. R., Sahai, V., Hersberger, K. E., Francis, I. R., & Wasnik, A. P. (2018) · Current Problems in Diagnostic Radiology · doi:10.1067/j.cpradiol.2018.07.016 · Cited by 45
MRI techniques for immunotherapy monitoring
Lau, D., Corrie, P. G., & Gallagher, F. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004708 · Cited by 44
Reassessing Patterns of Response to Immunotherapy with PET: From Morphology to Metabolism
Costa, L. B., Queiroz, M. A., Barbosa, F. D. G., Nunes, R. F., Zaniboni, E. C., Ruiz, M. F. D. C. M., Jardim, D. L. F., Marin, J. F. G., Cerri, G. G., & Buchpiguel, C. A. (2020) · Radiographics · doi:10.1148/rg.2021200093 · Cited by 44
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
Martin‐Romano, P., Álvarez, E. C., Ammari, S., Champiat, S., Hollebecque, A., Postel-Vinay, S. C., Baldini, C., Varga, A., Michot, J. M., Vuagnat, P., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2797 · Cited by 43
Pseudoprogression in Non–Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
Ferrara, R., Caramella, C., Besse, B., & Champiat, S. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.011 · Cited by 43
Immunotherapy Mythbusters in Head and Neck Cancer: The Abscopal Effect and Pseudoprogression
Lauber, K., & Dunn, L. A. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_238339 · Cited by 41
Non-invasive monitoring of the kinetic infiltration and therapeutic efficacy of nanoparticle-labeled chimeric antigen receptor T cells in glioblastoma via 7.0-Tesla magnetic resonance imaging
Xie, T., Chen, X., Fang, J., Xue, W., Zhang, J., Tong, H., Liu, H., Guo, Y., Yang, Y., & Zhang, W. (2020) · Cytotherapy · doi:10.1016/j.jcyt.2020.10.006 · Cited by 42
Pseudoprogression in lung cancer patients treated with immunotherapy
Chen, M., & Zeng, Y. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103531 · Cited by 40
Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
Manitz, J., D’Angelo, S. P., Apolo, A. B., Eggleton, S. P., Bajars, M., Bohnsack, O., & Gulley, J. L. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003302 · Cited by 41
Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors
Tozuka, T., Kitazono, S., Sakamoto, H., Yoshida, H., Amino, Y., Uematsu, S., Yoshizawa, T., Hasegawa, T., Uchibori, K., Yanagitani, N., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6704-z · Cited by 40
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 41
Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Park, H. J., Kim, G. H., Kim, K. W., Lee, C. W., Yoon, S., Chae, Y. K., Tirumani, S. H., & Ramaiya, N. H. (2021) · Cancers · doi:10.3390/cancers13010120 · Cited by 39
iRECIST and atypical patterns of response to immuno-oncology drugs
Ramón-Patiño, J. L., Schmid, S., Lau, S. C. M., Seymour, L., Gaudreau, P.-O., Li, J. J. N., Bradbury, P. A., & Calvo, E. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004849 · Cited by 39
Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Pozzessere, C., Bassanelli, M., Ceribelli, A., Rasul, S., Li, S., Prior, J. O., & Cicone, F. (2019) · Current Urology Reports · doi:10.1007/s11934-019-0938-9 · Cited by 37
Current Perspectives on Immunotherapy
Weber, J. S. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.09.003 · Cited by 37
Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis
Kaufman, H. L., Schwartz, L. H., William, W. N., Sznol, M., Fahrbach, K. R., Xu, Y., Masson, E., & Vergara-Silva, A. L. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2738-x · Cited by 38
Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma
Amrane, K., Legoupil, D., Quéré, G., Delcroix, O., Gouva, S., Schick, U., Salaün, P., Abgral, R., Alavi, Z., Keromnes, N., et al. (2019) · Medicine · doi:10.1097/md.0000000000016417 · Cited by 37
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M. J., Dubinett, S. M., Ferris, A. A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003956 · Cited by 46
Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know
Braschi‐Amirfarzan, M., Tirumani, S. H., Hodi, F. S., & Nishino, M. (2017) · Korean Journal of Radiology · doi:10.3348/kjr.2017.18.1.42 · Cited by 36
Principles of Immunotherapy in Melanoma
Onitilo, A. A., & Wittig, J. A. (2019) · Surgical Clinics of North America · doi:10.1016/j.suc.2019.09.009 · Cited by 38
Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
Refae, S., Gal, J., Brest, P., Giacchero, D., Borchiellini, D., Ebran, N., Peyrade, F., Guigay, J., Milano, G. A., & Saâda-Bouzid, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-60437-0 · Cited by 37
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors
Shen, P., Han, L., Ba, X., Qin, K., & Tu, S. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.678409 · Cited by 36
A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1
Somaiah, N., Chawla, S. P., Block, M. S., Morris, J. C., Do, K. T., Kim, J. W., Druta, M., Sankhala, K. K., Hwu, P., Jones, R. L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1847846 · Cited by 35
Imaging features of gadoxetic acid-enhanced MR imaging for evaluation of tumor-infiltrating CD8 cells and PD-L1 expression in hepatocellular carcinoma
Sun, L., Mu, L., Zhou, J. W., Tang, W., Zhang, L., Xie, S., Chen, J., & Wang, J. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02957-w · Cited by 37
Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma
McLean, L. S., Lim, A. M. L., Webb, A., Cavanagh, K., Thai, A. A., Magarey, M. J. R., Fox, C., Kleid, S. M., & Rischin, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.796197 · Cited by 35
Accuracy and feasibility of estimated tumour volumetry in primary gastric gastrointestinal stromal tumours: validation using semiautomated technique in 127 patients
Tirumani, S. H., Shinagare, A. B., O’Neill, A. C., Nishino, M., Rosenthal, M. H., & Ramaiya, N. H. (2015) · European Radiology · doi:10.1007/s00330-015-3829-6 · Cited by 33
Response Evaluation and Survival Prediction After PD-1 Immunotherapy in Patients with Non–Small Cell Lung Cancer: Comparison of Assessment Methods
Ayati, N., Lee, S. T., Zakavi, S. R., Cheng, M., Lau, E. W. F., Parakh, S., Pathmaraj, K., & Scott, A. M. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.254508 · Cited by 33
Some statistical considerations in the clinical development of cancer immunotherapies
Huang, B. (2017) · Pharmaceutical Statistics · doi:10.1002/pst.1835 · Cited by 32
Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons
Choi, B. D., Curry, W. T., Carter, B. S., & Maus, M. V. (2018) · Neurosurgical FOCUS · doi:10.3171/2018.2.focus17788 · Cited by 32
Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy
Nakamoto, R., Zaba, L. C., Rosenberg, J., Reddy, S. A., Nobashi, T. W., Davidzon, G., Aparici, C. M., Nguyen, J., Moradi, F., Iagaru, A. H., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04792-0 · Cited by 32
Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives
Middleton, M. R., Höeller, C., Michielin, O. A., Robert, C., Caramella, C., Öhrling, K., & Hauschild, A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0994-4 · Cited by 31
Cancer immunotherapy response prediction from multi-modal clinical and image data using semi-supervised deep learning
Wang, X., Jiang, Y., Chen, H., Zhang, T., Han, Z., Chen, C., Yuan, Q., Xiong, W., Wang, W., Li, G., et al. (2023) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2023.109793 · Cited by 33
Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement
Tsimberidou, A. M., Levit, L. A., Schilsky, R. L., Averbuch, S. D., Chen, D. S., Kirkwood, J. M., McShane, L. M., Sharon, E., Mileham, K. F., & Postow, M. A. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00145 · Cited by 30
A Dendritic Cell Vaccine Combined With Radiotherapy Activates the Specific Immune Response in Patients With Esophageal Cancer
Wang, C., Pu, J., Yu, H., Liu, Y., Yan, H., He, Z., & Feng, X. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000155 · Cited by 30
iRECIST: A clarification of tumour response assessment in the immunotherapy era
Ferté, C., & Marabelle, A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.02.015 · Cited by 30
Site-specific Response to Nivolumab in Renal Cell Carcinoma
Negishi, T., Furubayashi, N., Nakagawa, T., Nishiyama, N., Kitamura, H., Hori, Y., Kuroiwa, K., Son, Y., Seki, N., Tomoda, T., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.14913 · Cited by 29
FDG-PET/CT in the Monitoring of Lymphoma Immunotherapy Response: Current Status and Future Prospects
Al‐Ibraheem, A., Abdlkadir, A. S., Juweid, M. E., Al-Rabi, K. H., Ma’koseh, M., Abdel‐Razeq, H., & Mansour, A. H. (2023) · Cancers · doi:10.3390/cancers15041063 · Cited by 30
Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade
Guan, Y., Feng, D., Yin, B., Li, K., & Wang, J. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221096877 · Cited by 28
Tracking Cellular and Immune Therapies in Cancer
Kurtz, D. M., & Gambhir, S. S. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-411638-2.00008-2 · Cited by 27
Hyperprogression Under Immune Checkpoint-Based Immunotherapy—Current Understanding, The Role of PD-1/PD-L1 Tumour-Intrinsic Signalling, Future Directions and a Potential Large Animal Model
Kocikowski, M., Dziubek, K., & Parys, M. (2020) · Cancers · doi:10.3390/cancers12040804 · Cited by 27
Management of cutaneous melanoma: radiologists challenging and risk assessment
Granata, V., Simonetti, I., Fusco, R., Setola, S. V., Izzo, F., Scarpato, L., Vanella, V., Festino, L., Simeone, E., Ascierto, P. A., et al. (2022) · La radiologia medica · doi:10.1007/s11547-022-01522-4 · Cited by 26
Noninvasive radiomic biomarkers for predicting pseudoprogression and hyperprogression in patients with non-small cell lung cancer treated with immune checkpoint inhibition
Li, Y., Wang, P., Xu, J., Shi, X., Yin, T., & Teng, F. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2312628 · Cited by 27
Immunotherapy in prostate cancer: review of the current evidence
Fernández‐García, E. M., Vera-Badillo, F., Pérez‐Valderrama, B., Matos-Pita, A. S., & Durán, I. (2014) · Clinical & Translational Oncology · doi:10.1007/s12094-014-1259-6 · Cited by 28
Optimal design of trials to demonstrate the utility of genomically‐guided therapy: Putting Precision Cancer Medicine to the test
Dienstmann, R., Rodon, J. A., & Tabernero, J. M. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.06.014 · Cited by 26
Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
Weidhaas, J. B., Marco, N. D., Scheffler, A. W., Kalbasi, A. K., Wilenius, K., Rietdorf, E., Gill, J. M., Heilig, M., Desler, C., Chin, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003625 · Cited by 29
Immunotherapy of melanoma
Kee, D., & McArthur, G. A. (2016) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2016.07.014 · Cited by 26
The role of radiology in the evaluation of the immunotherapy efficacy
Calandri, M., Solitro, F., Angelino, V., Moretti, F., & Veltri, A. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.130 · Cited by 25
Which criteria should we use to evaluate the efficacy of immune-checkpoint inhibitors?
Kataoka, Y., & Hirano, K. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.04.17 · Cited by 25
Ipilimumab: an investigational immunotherapy for glioblastoma
Youssef, G., & Dietrich, J. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1826436 · Cited by 24
A Phase 2 Study of Camrelizumab for Advanced Hepatocellular Carcinoma: Two-Year Outcomes and Continued Treatment beyond First RECIST-Defined Progression
Ren, Z., Qin, S., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., Zhu, H., Fang, W. J., et al. (2021) · Liver Cancer · doi:10.1159/000516470 · Cited by 24
Imaging assessment of toxicity related to immune checkpoint inhibitors
Berz, A. M., Boughdad, S., Violi, N. V., Digklia, A., Dromain, C., Dunet, V., & Durán, R. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1133207 · Cited by 26
Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
Liang, H., Xu, Y., Chen, M., Zhong, W., Wang, M., & Zhao, J. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13367 · Cited by 25
Advances in evidence‐based medicine for immunotherapy of non‐small cell lung cancer
Dong, J., Li, B., Zhou, Q., & Huang, D. (2018) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12322 · Cited by 22
The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice
Raimondi, A., Randon, G., Sepe, P., Claps, M., Verzoni, E., de Braud, F., & Procopio, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174263 · Cited by 24
Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trial
Tong, T. M. L., van der Kooij, M. K., Speetjens, F. M., van Erkel, A. R., van der Meer, R. W., Lutjeboer, J., van Meerten, E. L. V. P., Martini, C. H., Zoethout, R. W. M., Tijl, F. G. J., et al. (2022) · Trials · doi:10.1186/s13063-022-06036-y · Cited by 23
Immuno-Oncology: The Third Paradigm in Early Drug Development
Martín-Liberal, J., Hierro, C., de Olza, M. O., & Rodon, J. A. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0471-4 · Cited by 24
18F-Fludeoxyglucose PET/Computed Tomography for Assessing Tumor Response to Immunotherapy and Detecting Immune-Related Side Effects
Prigent, K., & Aide, N. (2019) · PET Clinics · doi:10.1016/j.cpet.2019.08.006 · Cited by 24
Hyperprogression under immunotherapy: a new form of immunotherapy response?—a narrative literature review
Lin, M., Vanneste, B., Yu, Q.-W., Chen, Z., Peng, J., & Cai, X. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-21-575 · Cited by 19
Dynamic Contrast-Enhanced Computed Tomography as a Potential Biomarker in Patients With Metastatic Renal Cell Carcinoma
Mains, J. R., Donskov, F. N., Pedersen, E. M., Madsen, H. H. T., & Rasmussen, F. (2014) · Investigative Radiology · doi:10.1097/rli.0000000000000058 · Cited by 22
The evolving landscape of criteria for evaluating tumor response in the era of cancer immunotherapy: From Karnofsky to iRECIST
Inno, A., Russo, G. L., Salgarello, M., Corrao, G., Casolino, R., Galli, G., Modena, A., Romano, L., Pusceddu, S., Greco, F. G., et al. (2018) · Tumori Journal · doi:10.1177/0300891618766173 · Cited by 22

Authors: Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S.
Affiliations: Brigham and Women's Hospital (US)
Authors' Affiliations: Departments of 1Radiology and 2Medical Oncology and Department of Medicine, Dana-Farber Cancer Institute and Brigham and Women's Hospital; and 3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
Corresponding author: Nishino, Mizuki
ORCID: Nishino, Mizuki
Ramaiya, Nikhil H.
Hodi, F. Stephen
Venue: Clinical Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2013-07-15
Volume: 19
Issue: 14
Pages: 3936-3943
ISSN: 1078-0432 (ISSN-L)
1557-3265
DOI: 10.1158/1078-0432.ccr-13-0895
PMC: PMC3740724
OpenAlex: W2153778867
Cited by: 522
References: 21
Citations by year: 2026: 19 · 2025: 21 · 2024: 27 · 2023: 53 · 2022: 51 · 2021: 56 · 2020: 76 · 2019: 57 · 2018: 49 · 2017: 39 · 2016: 36 · 2015: 23 · 2014: 13 · 2013: 2
FWCI: 13.12
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Clinical Cancer Research (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5k23ca157631-02)
National Cancer Institute (K23-CA157631, 1K23CA157631)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
Keywords: immune-related response criteria, tumor response assessment, immunotherapy, advanced melanoma, ipilimumab, interobserver variability, time to progression, best overall response, RECIST
MeSH terms: Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Models, Biological, Terminology as Topic, Models, Statistical, Treatment Outcome, Clinical Trials, Phase II as Topic, Disease-Free Survival, Statistics, Nonparametric, Kaplan-Meier Estimate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks